##### Table of Contents









UNITED STATES SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549





Form 10-Q/ A





|           |  |                                                                                             
|---------- |  | --------------------------------------------------------------------------------------------
|(Mark One) |  |                                                                                             
|þ          |  | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934 
|           |  | For the quarterly period ended September 30, 2004                                           
|          
|or        
|          
|o          |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
|           |  | For the transition period
    from             to             .                             

Commission file number: 01-10920





Fisher Scientific International Inc.


(Exact name of registrant as specified in its charter)


|                                                                            |  |                                                   
|--------------------------------------------------------------------------- |  | --------------------------------------------------
|Delaware(State or other jurisdiction of
    incorporation or organization)  |  | 02-0451017(I.R.S. Employer
    Identification No.)
|                                                                           
|Liberty Lane Hampton, New Hampshire(Address of principal executive offices) |  | 03842(Zip Code)                                   

Registrants telephone number, including area code:


(603) 926-5911





þ o


þ o












---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


FORM 10-Q/ A


For the Quarterly Period Ended September 30, 2004


Explanatory Note:


Fisher Scientific International Inc. is filing this Quarterly
Report on Form  10-Q/ A as an amendment to its
Quarterly Report on Form 10-Q, originally filed on
November 9, 2004, for the purpose of giving effect to the
restatement of the Companys Financial Statements for the
quarterly period ended September 30, 2004. For additional
information regarding the restatements, refer to Note 1 of
the Notes to Financial Statements in Item 1 of Part I.
Only Items 1, 2 and 4 of Part I of this
Form 10-Q/ A have been modified to reflect the restated
Financial Statements and related disclosures. This
Form 10-Q/ A only reflects the effects of the restatement
and does not otherwise reflect events occurring after the filing
of the original Form 10-Q or otherwise modify or update
those disclosures.




---










FISHER SCIENTIFIC INTERNATIONAL INC.


FORM 10-Q/ A


For the Quarterly Period Ended September 30, 2004


INDEX


|                                            |  |   |    |                                                                                                                            |  |          |    | 
|------------------------------------------- |  | - | -- | -------------------------------------------------------------------------------------------------------------------------- |  | -------- | -- | 
|                                            |  |   |    |                                                                                                                            |  | Page No. |   
|                                            |  |   |    |                                                                                                                            |  |          |   
|Part I                                      |  |  |    | FINANCIAL INFORMATION:                                                                                                     |  |          |    | 
|Item 1                                      |  |  |    | Financial Statements (as restated):                                                                                        |  |          | 2  | 
|                                            |  |   |    | Introduction to the Financial Statements                                                                                   |  |          | 2  | 
|                                            |  |   |    | Statement of Operations  Three
    and Nine Months Ended September 30, 2004 and 2003                                      |  |          | 3  | 
|                                            |  |   |    | Balance Sheet 
    September 30, 2004 and December 31, 2003                                                               |  |          | 4  | 
|                                            |  |   |    | Statement of Cash Flows  Nine
    Months Ended September 30, 2004 and 2003                                                |  |          | 5  | 
|                                            |  |   |    | Statement of Changes in Stockholders
    Equity and Other Comprehensive
    Income  Nine Months Ended September 30, 2004 |  |          | 6  | 
|                                            |  |   |    | Notes to Financial Statements                                                                                              |  |          | 7  | 
|Item 2                                      |  |  |    | Managements Discussion and Analysis
    of Financial Condition and Results of Operations                                  |  |          | 25 | 
|Item 3                                      |  |  |    | Quantitative and Qualitative Disclosures
    About Market Risk                                                             |  |          | 33 | 
|Item 4                                      |  |  |    | Controls and Procedures                                                                                                    |  |          | 34 | 
|                                           
|Part II                                     |  |  |    | OTHER INFORMATION:                                                                                                         |  |          | 36 | 
|Item 4                                      |  |  |    | Submission of Matters to a Vote of Security
    Holders                                                                    |  |          | 36 | 
|Item 6                                      |  |  |    | Exhibits and Reports on Form 8-K                                                                                           |  |          | 36 | 
|SIGNATURE                                   |  |   | 37 |                                                                                                                           
|Certifications                              |  |   |    |                                                                                                                           
|Ex-31.1 Section 302 Certification of C.E.O.
|Ex-31.2 Section 302 Certification of C.F.O.
|Ex-32.1 Section 906 Certification of C.E.O.
|Ex-32.2 Section 906 Certification of C.F.O.



1



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.





PART 1  FINANCIAL INFORMATION







|         |                     
|-------- | --------------------
|Item 1  | Financial Statements




INTRODUCTION TO THE FINANCIAL STATEMENTS






2



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.





STATEMENT OF OPERATIONS


(In millions, except per share data)


(Unaudited)


|                                            |         |                    |         |       |                   |   |               |      |  |   |         |      |  |   |         |      | 
|------------------------------------------- | ------- | ------------------ | ------- | ----- | ----------------- | - | ------------- | ---- |  | - | ------- | ---- |  | - | ------- | ---- | 
|                                            |         | Three Months Ended |         |       | Nine Months Ended |  
|                                            |         | September 30,      |         |       | September 30,     |  
|                                            |         |                    |         |       |                   |  
|                                            |         | 2004               |         |       | 2003              |   |               | 2004 |  |   | 2003    |     
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     
|                                            |         | (As Restated,      |         |       |                   |   | (As Restated, |      |  |  
|                                            |         | See Note 1)        |         |       |                   |   | See Note 1)   |      |  |  
|Sales                                       |         | $                  | 1,263.0 |       |                   | $ | 890.0         |      |  | $ | 3,331.6 |      |  | $ | 2,587.9 |     
|Cost of sales                               |         |                    | 900.1   |       |                   |   | 651.0         |      |  |   | 2,385.0 |      |  |   | 1,902.6 |     
|Selling, general and administrative expense |         |                    | 269.1   |       |                   |   | 170.9         |      |  |   | 698.9   |      |  |   | 489.4   |     
|Restructuring expense                       |         |                    | 1.6     |       |                   |   |              |      |  |   | 1.6     |      |  |   |        |     
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     
|Income from operations                      |         |                    | 92.2    |       |                   |   | 68.1          |      |  |   | 246.1   |      |  |   | 195.9   |     
|Interest expense                            |         |                    | 28.7    |       |                   |   | 23.4          |      |  |   | 73.7    |      |  |   | 62.3    |     
|Other expense, net                          |         |                    | 14.9    |       |                   |   | 11.6          |      |  |   | 15.3    |      |  |   | 59.2    |     
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     
|Income before income taxes                  |         |                    | 48.6    |       |                   |   | 33.1          |      |  |   | 157.1   |      |  |   | 74.4    |     
|Income tax provision                        |         |                    | 12.5    |       |                   |   | 5.4           |      |  |   | 41.7    |      |  |   | 14.6    |     
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     
|Net income                                  |         | $                  | 36.1    |       |                   | $ | 27.7          |      |  | $ | 115.4   |      |  | $ | 59.8    |     
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     
|Net income per common share:                |         |                    |         |       |                   |   |               |      |  |   |         |      |  |   |         |     
|                                            | Basic   |                    | $       | 0.36  |                   |   | $             | 0.50 |  |   | $       | 1.52 |  |   | $       | 1.09 | 
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     
|                                            | Diluted |                    | $       | 0.34  |                   |   | $             | 0.47 |  |   | $       | 1.42 |  |   | $       | 1.02 | 
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     
|Weighted average common shares outstanding: |         |                    |         |       |                   |   |               |      |  |   |         |      |  |   |         |     
|                                            | Basic   |                    |         | 99.2  |                   |   |               | 55.2 |  |   |         | 75.7 |  |   |         | 54.9 | 
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     
|                                            | Diluted |                    |         | 106.0 |                   |   |               | 59.4 |  |   |         | 81.0 |  |   |         | 58.5 | 
|                                            |         |                    |         |       |                   |   |               |      |  |   |         |     



3



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.





BALANCE SHEET


(In millions, except share data)


|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |         |         |        |         |         | 
|------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------- | ------------------------------------------ | ------- | ------------ | ------- | ------- | ------ | ------- | ------- | 
|                                     |                                                                                                                                                                                                                                  | September 30,              |                                            |         | December 31, |        
|                                     |                                                                                                                                                                                                                                  | 2004                       |                                            |         | 2003         |        
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|                                     |                                                                                                                                                                                                                                  | (As Restated,              |                                            |         |             
|                                     |                                                                                                                                                                                                                                  | See Note 1)                |                                            |         |             
|                                     |                                                                                                                                                                                                                                  | (Unaudited)                |                                            |         |             
|ASSETS                              
|Current assets:                      |                                                                                                                                                                                                                                  |                            |                                            |         |              |         |         |       
|                                     | Cash and cash equivalents                                                                                                                                                                                                        |                            | $                                          | 296.4   |              |         | $       | 83.8   |        
|                                     | Accounts receivable, net                                                                                                                                                                                                         |                            |                                            | 646.4   |              |         |         | 432.7  |        
|                                     | Inventories                                                                                                                                                                                                                      |                            |                                            | 651.4   |              |         |         | 355.4  |        
|                                     | Other current assets                                                                                                                                                                                                             |                            |                                            | 215.1   |              |         |         | 138.9  |        
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|                                     |                                                                                                                                                                                                                                  | Total current assets       |                                            |         | 1,809.3      |         |         |        | 1,010.8 |        
|Property, plant and equipment        |                                                                                                                                                                                                                                  |                            | 745.0                                      |         |              |         | 440.9   |       
|Goodwill                             |                                                                                                                                                                                                                                  |                            | 4,193.4                                    |         |              |         | 1,006.9 |       
|Intangible assets                    |                                                                                                                                                                                                                                  |                            | 1,044.1                                    |         |              |         | 241.0   |       
|Other assets                         |                                                                                                                                                                                                                                  |                            | 186.6                                      |         |              |         | 159.8   |       
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|                                     |                                                                                                                                                                                                                                  | Total assets               |                                            | $       | 7,978.4      |         |         | $      | 2,859.4 |        
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|                                    
|LIABILITIES AND STOCKHOLDERS EQUITY
|Current liabilities:                 |                                                                                                                                                                                                                                  |                            |                                            |         |              |         |         |       
|                                     | Short-term debt                                                                                                                                                                                                                  |                            | $                                          | 38.1    |              |         | $       | 12.0   |        
|                                     | Accounts payable                                                                                                                                                                                                                 |                            |                                            | 448.2   |              |         |         | 377.7  |        
|                                     | Accrued and other current liabilities                                                                                                                                                                                            |                            |                                            | 465.4   |              |         |         | 258.8  |        
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|                                     |                                                                                                                                                                                                                                  | Total current liabilities  |                                            |         | 951.7        |         |         |        | 648.5   |        
|Long-term debt                       |                                                                                                                                                                                                                                  |                            | 2,602.5                                    |         |              |         | 1,386.1 |       
|Other liabilities                    |                                                                                                                                                                                                                                  |                            | 752.5                                      |         |              |         | 249.4   |       
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|                                     |                                                                                                                                                                                                                                  | Total liabilities          |                                            |         | 4,306.7      |         |         |        | 2,284.0 |        
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|Commitments and contingencies        |                                                                                                                                                                                                                                  |                            |                                            |         |              |         |         |       
|Stockholders equity:                |                                                                                                                                                                                                                                  |                            |                                            |         |              |         |         |       
|                                     | Preferred stock ($0.01 par value; 15,000,000 shares
    authorized; none outstanding)                                                                                                                                            |                            |                                            |        |              |         |         |       |        
|                                     | Common stock ($0.01 par value; 500,000,000 shares
    authorized; 117,214,223 and 63,218,083 shares issued; and
    116,959,248 and 62,955,438 shares outstanding at
    September 30, 2004 and December 31, 2003, respectively) |                            |                                            | 1.1     |              |         |         | 0.6    |        
|                                     | Capital in excess of par value                                                                                                                                                                                                   |                            |                                            | 3,955.3 |              |         |         | 964.5  |        
|                                     | Accumulated deficit                                                                                                                                                                                                              |                            |                                            | (311.1  | )            |         |         | (426.5 | )      
|                                     | Accumulated other comprehensive income                                                                                                                                                                                           |                            |                                            | 30.4    |              |         |         | 40.0   |        
|                                     | Treasury stock, at cost (254,975 and 262,645 shares at
    September 30, 2004 and December 31, 2003, respectively)                                                                                                               |                            |                                            | (4.0    | )            |         |         | (3.2   | )      
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|                                     |                                                                                                                                                                                                                                  | Total stockholders equity |                                            |         | 3,671.7      |         |         |        | 575.4   |        
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        
|                                     |                                                                                                                                                                                                                                  |                            | Total liabilities and stockholders equity |         | $            | 7,978.4 |         |        | $       | 2,859.4 | 
|                                     |                                                                                                                                                                                                                                  |                            |                                            |         |              |        



4



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.





STATEMENT OF CASH FLOWS


(In millions)


(Unaudited)


|                                                             |                                                                                   |                                              |                           |         |        |       |       |         |        |       |  
|------------------------------------------------------------ | --------------------------------------------------------------------------------- | -------------------------------------------- | ------------------------- | ------- | ------ | ----- | ----- | ------- | ------ | ----- | -
|                                                             |                                                                                   | Nine Months Ended                            |                          
|                                                             |                                                                                   | September 30,                                |                          
|                                                             |                                                                                   |                                              |                          
|                                                             |                                                                                   | 2004                                         |                           |         | 2003   |      
|                                                             |                                                                                   |                                              |                           |         |        |      
|                                                             |                                                                                   | (As Restated,                                |                           |         |       
|                                                             |                                                                                   | See Note 1)                                  |                           |         |       
|Cash flows from operating activities:                        |                                                                                   |                                              |                           |         |        |       |       |        
|                                                             | Net income                                                                        |                                              | $                         | 115.4   |        |       | $     | 59.8    |       
|                                                             | Adjustments to reconcile net income to cash provided by
    operating activities: |                                              |                           |         |        |       |       |         |       
|                                                             |                                                                                   | Depreciation and amortization                |                           |         | 92.2   |       |       |         | 58.2   |      
|                                                             |                                                                                   | Call premiums and deferred financing charges |                           |         | 15.6   |       |       |         | 46.5   |      
|                                                             |                                                                                   | Deferred income taxes                        |                           |         | 12.8   |       |       |         | 0.2    |      
|                                                             |                                                                                   | Other noncash expenses                       |                           |         | 1.1    |       |       |         | 16.2   |      
|                                                             |                                                                                   | Restructuring expense                        |                           |         | 1.6    |       |       |         |       |      
|                                                             |                                                                                   | Changes in working capital                   |                           |         |        |       |       |         |        |      
|                                                             |                                                                                   |                                              | Accounts receivables, net |         |        | (2.3  | )     |         |        | (18.6 | )
|                                                             |                                                                                   |                                              | Inventories               |         |        | 33.0  |       |         |        | 26.7  |  
|                                                             |                                                                                   |                                              | Accounts payable          |         |        | (0.7  | )     |         |        | 11.3  |  
|                                                             |                                                                                   |                                              | Other assets              |         |        | 7.9   |       |         |        | (54.0 | )
|                                                             |                                                                                   |                                              | Other liabilities         |         |        | (34.1 | )     |         |        | 9.3   |  
|                                                             |                                                                                   |                                              |                           |         |        |      
|                                                             |                                                                                   | Cash provided by operating activities        |                           |         | 242.5  |       |       |         | 155.6  |      
|                                                             |                                                                                   |                                              |                           |         |        |      
|Cash flows from investing activities:                        |                                                                                   |                                              |                           |         |        |       |       |        
|                                                             | Acquisitions, net of cash acquired                                                |                                              |                           | (326.2  | )      |       |       | (649.0  | )     
|                                                             | Capital expenditures                                                              |                                              |                           | (57.1   | )      |       |       | (50.1   | )     
|                                                             | Purchase of financial instruments                                                 |                                              |                           |        |        |       |       | (15.6   | )     
|                                                             | Proceeds from sale of property, plant and equipment                               |                                              |                           | 0.2     |        |       |       | 0.3     |       
|                                                             | Other investments                                                                 |                                              |                           | (2.5    | )      |       |       | 1.1     |       
|                                                             |                                                                                   |                                              |                           |         |        |      
|                                                             |                                                                                   | Cash used in investing activities            |                           |         | (385.6 | )     |       |         | (713.3 | )    
|                                                             |                                                                                   |                                              |                           |         |        |      
|Cash flows from financing activities:                        |                                                                                   |                                              |                           |         |        |       |       |        
|                                                             | Proceeds from sale of common stock                                                |                                              |                           |        |        |       |       | 261.0   |       
|                                                             | Proceeds from stock options exercised                                             |                                              |                           | 92.1    |        |       |       | 11.5    |       
|                                                             | Long-term debt proceeds                                                           |                                              |                           | 1,016.8 |        |       |       | 1,308.0 |       
|                                                             | Payments of long-term debt                                                        |                                              |                           | (731.4  | )      |       |       | (728.1  | )     
|                                                             | Changes in short-term debt, net                                                   |                                              |                           | 5.3     |        |       |       | (16.6   | )     
|                                                             | Deferred financing costs                                                          |                                              |                           | (24.5   | )      |       |       | (27.1   | )     
|                                                             | Call premiums                                                                     |                                              |                           | (2.3    | )      |       |       | (27.3   | )     
|                                                             |                                                                                   |                                              |                           |         |        |      
|                                                             |                                                                                   | Cash provided by financing activities        |                           |         | 356.0  |       |       |         | 781.4  |      
|                                                             |                                                                                   |                                              |                           |         |        |      
|Effect of exchange rate changes on cash and cash equivalents |                                                                                   |                                              | (0.3                      | )       |        |       | 3.4   |        
|                                                             |                                                                                   |                                              |                           |         |        |      
|Net change in cash and cash equivalents                      |                                                                                   |                                              | 212.6                     |         |        |       | 227.1 |        
|Cash and cash equivalents  beginning of period              |                                                                                   |                                              | 83.8                      |         |        |       | 38.8  |        
|                                                             |                                                                                   |                                              |                           |         |        |      
|Cash and cash equivalents  end of period                    |                                                                                   | $                                            | 296.4                     |         |        | $     | 265.9 |        
|                                                             |                                                                                   |                                              |                           |         |        |      



5



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.





STATEMENT OF CHANGES IN STOCKHOLDERS EQUITY


AND OTHER COMPREHENSIVE INCOME


(In millions, except share data)


(As Restated, see Note 1)


(Unaudited)


|                              |                                          |                                       |             |            |           |   |     |           |           |   |             |         |  |             |       |               |                 |   |         |        |  |   |        |       |               |        |      |      |       |  |         |         |   |   |      |      |   |   |         |         |   |  |   |       |       | 
|----------------------------- | ---------------------------------------- | ------------------------------------- | ----------- | ---------- | --------- | - | --- | --------- | --------- | - | ----------- | ------- |  | ----------- | ----- | ------------- | --------------- | - | ------- | ------ |  | - | ------ | ----- | ------------- | ------ | ---- | ---- | ----- |  | ------- | ------- | - | - | ---- | ---- | - | - | ------- | ------- | - |  | - | ----- | ----- | 
|                              |                                          |                                       |             |            |           |   |     |           |           |   |             |         |  | Accumulated |       |               |                 |   |         |        | 
|                              |                                          |                                       |             | Capital in |           |   |     |           | Shares to |   |             |         |  | Other       |       |               | Treasury Stock, |   |         |        |  |  
|                              |                                          | Common Stock                          |             |            | Excess of |   |     | Shares    |           |   | be          |         |  |             |       | Comprehensive |                 |   | at Cost |        |  |   |        | Other |              
|                              |                                          |                                       |             |            | Par       |   |     | Deposited |           |   | Distributed |         |  | Accumulated |       |               | Income          |   |         |        |  |   |        |       | Comprehensive |       
|                              |                                          | Shares                                |             |            | Amount    |   |     | Value     |           |   | in Trust    |         |  | from Trust  |       |               | Deficit         |   |         | (Loss) |  |   | Shares |       |               | Amount |      |      | Total |  |         | Income  |  
|                              |                                          |                                       |             |            |           |   |     |           |           |   |             |         |  |             |       |               |                 |   |         |        |  |   |        |       |               |        |      |      |       |  |         |         |  
|Balance at January  1, 2004   |                                          |                                       | 63,218,083  |            |           | $ | 0.6 |           |           | $ | 964.5       |         |  | $           | (25.5 | )             |                 | $ | 25.5    |        |  | $ | (426.5 | )     |               | $      | 40.0 |      |       |  | 262,645 |         |   | $ | (3.2 | )    |   | $ | 575.4   |         |   |  |   |      
|                              | Net income                               |                                       |             |           |           |   |     |          |           |   |             |        |  |             |       |              |                 |   |         |       |  |   |        | 115.4 |               |        |      |     |       |  |         |        |   |   |      |     |   |   |         | 115.4   |   |  | $ | 115.4 |      
|                              | Foreign currency translation adjustment  |                                       |             |           |           |   |     |          |           |   |             |        |  |             |       |              |                 |   |         |       |  |   |        |      |               |        |      | (6.2 | )     |  |         |        |   |   |      |     |   |   |         | (6.2    | ) |  |   | (6.2  | )    
|                              | Unrealized investment gains (losses)     |                                       |             |           |           |   |     |          |           |   |             |        |  |             |       |              |                 |   |         |       |  |   |        |      |               |        |      | 2.1  |       |  |         |        |   |   |      |     |   |   |         | 2.1     |   |  |   | 2.1   |      
|                              | Unrealized loss on cash flow hedges      |                                       |             |           |           |   |     |          |           |   |             |        |  |             |       |              |                 |   |         |       |  |   |        |      |               |        |      | (5.5 | )     |  |         |        |   |   |      |     |   |   |         | (5.5    | ) |  |   | (5.5  | )    
|                              |                                          |                                       |             |            |           |   |     |           |           |   |             |         |  |             |       |               |                 |   |         |        |  |   |        |       |               |        |      |      |       |  |         |         |  
|                              |                                          | Subtotal  other comprehensive income |             |            |           |   |     |           |           |   |             |         |  |             |       |               |                 |   |         |        |  |   |        |       |               |        |      |      |       |  |         |         |   |   |      |      |   |   |         |         |   |  |   | $     | 105.8 | 
|                              |                                          |                                       |             |            |           |   |     |           |           |   |             |         |  |             |       |               |                 |   |         |        |  |   |        |       |               |        |      |      |       |  |         |         |  
|                              | Proceeds from stock options              |                                       |             | 3,361,630  |           |   |     |          |           |   |             | 92.1    |  |             |       |              |                 |   |         |       |  |   |        |      |               |        |      |     |       |  |         |        |   |   |      |     |   |   |         | 92.1    |   |  |   |       |      
|                              | Tax benefit from stock options           |                                       |             |           |           |   |     |          |           |   |             | 18.1    |  |             |       |              |                 |   |         |       |  |   |        |      |               |        |      |     |       |  |         |        |   |   |      |     |   |   |         | 18.1    |   |  |   |       |      
|                              | Acquisition of Apogent Technologies Inc. |                                       |             | 50,634,510 |           |   |     | 0.5       |           |   |             | 2,879.7 |  |             |       |              |                 |   |         |       |  |   |        |      |               |        |      |     |       |  |         |        |   |   |      |     |   |   |         | 2,880.2 |   |  |   |       |      
|                              | Acquisition of Treasury Stock            |                                       |             |           |           |   |     |          |           |   |             |        |  |             |       |              |                 |   |         |       |  |   |        |      |               |        |      |     |       |  |         | 49,843  |   |   |      | (3.0 | ) |   |         | (3.0    | ) |  |   |       |      
|                              | Trust activity                           |                                       |             |           |           |   |     |          |           |   |             | 0.9     |  |             |       |               |                 |   |         |        |  |   |        |      |               |        |      |     |       |  |         | (57,513 | ) |   |      | 2.2  |   |   |         | 3.1     |   |  |   |       |      
|                              |                                          |                                       |             |            |           |   |     |           |           |   |             |         |  |             |       |               |                 |   |         |        |  |   |        |       |               |        |      |      |       |  |         |         |  
|Balance at September 30, 2004 |                                          |                                       | 117,214,223 |            |           | $ | 1.1 |           |           | $ | 3,955.3     |         |  | $           | (25.5 | )             |                 | $ | 25.5    |        |  | $ | (311.1 | )     |               | $      | 30.4 |      |       |  | 254,975 |         |   | $ | (4.0 | )    |   | $ | 3,671.7 |         |   |  |   |      
|                              |                                          |                                       |             |            |           |   |     |           |           |   |             |         |  |             |       |               |                 |   |         |        |  |   |        |       |               |        |      |      |       |  |         |         |  



6



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS


(Unaudited)







|         |                                      
|-------- | -------------------------------------
|Note 1  | Formation, Background and Restatement





| |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
| | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| | 1. Scientific products and services segment provides
    products and services primarily to entities conducting
    scientific research, including drug discovery and drug
    development, quality and process control and basic research and
    development. This segment manufactures and distributes a broad
    range of biochemicals and bioreagents; organic and inorganic
    chemicals; sera; cell culture media; sterile liquid-handling
    systems; microbiology media and related products; scientific
    consumable products, instruments and equipment; safety and
    personal protection products; and other consumables and
    supplies. Additionally, this segment provides services to
    pharmaceutical and biotechnology companies engaged in clinical
    trials, including specialized packaging, over-encapsulation,
    labeling and distribution for phase III and phase IV
    clinical trials, as well as combinatorial chemistry,
    custom-chemical synthesis, supply-chain management and a number
    of other services.
|
| | 2. Healthcare products and servicessegment
    manufactures and distributes a wide array of diagnostic kits and
    reagents, equipment, instruments, medical devices and other
    consumable products to hospitals and group-purchasing
    organizations, clinical laboratories, reference laboratories,
    physicians offices and original equipment manufacturers.
    In addition we also manufacture and distribute ear, nose and
    throat medical devices outside the U.S. This segment also
    provides outsourced manufacturing services for diagnostic
    reagents, calibrators and controls to the healthcare and
    pharmaceutical industries.                                                                                                                                                                                                                                                                                                                                                                                            
|
| | 3. Laboratory workstationssegment manufactures and
    sells laboratory workstations and fume hoods and provides
    lab-design services for pharmaceutical and biotechnology
    customers, colleges, universities and secondary schools,
    hospitals and reference labs.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  



Restatement of Financial Statements








7



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)










8



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




STATEMENT OF OPERATIONS


(In millions, except per share data)


|                                            |         |                    |         |       |                    |   |               |          |  |   |             |      |  |   |         |      | 
|------------------------------------------- | ------- | ------------------ | ------- | ----- | ------------------ | - | ------------- | -------- |  | - | ----------- | ---- |  | - | ------- | ---- | 
|                                            |         | Three Months Ended |         |       | Nine Months Ended  |  
|                                            |         | September 30, 2004 |         |       | September 30, 2004 |  
|                                            |         |                    |         |       |                    |  
|                                            |         | As Previously      |         |       |                    |   | As Previously |          |  |  
|                                            |         | Reported           |         |       | As Restated        |   |               | Reported |  |   | As Restated |     
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     
|Sales                                       |         | $                  | 1,263.0 |       |                    | $ | 1,263.0       |          |  | $ | 3,331.6     |      |  | $ | 3,331.6 |     
|Cost of sales                               |         |                    | 900.1   |       |                    |   | 900.1         |          |  |   | 2,385.0     |      |  |   | 2,385.0 |     
|Selling, general and administrative expense |         |                    | 269.1   |       |                    |   | 269.1         |          |  |   | 698.9       |      |  |   | 698.9   |     
|Restructuring expense                       |         |                    | 1.6     |       |                    |   | 1.6           |          |  |   | 1.6         |      |  |   | 1.6     |     
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     
|Income from operations                      |         |                    | 92.2    |       |                    |   | 92.2          |          |  |   | 246.1       |      |  |   | 246.1   |     
|Interest expense                            |         |                    | 29.6    |       |                    |   | 28.7          |          |  |   | 74.6        |      |  |   | 73.7    |     
|Other expense, net                          |         |                    | 54.1    |       |                    |   | 14.9          |          |  |   | 54.5        |      |  |   | 15.3    |     
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     
|Income before income taxes                  |         |                    | 8.5     |       |                    |   | 48.6          |          |  |   | 117.0       |      |  |   | 157.1   |     
|Income tax (benefit) provision              |         |                    | (2.3    | )     |                    |   | 12.5          |          |  |   | 26.9        |      |  |   | 41.7    |     
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     
|Net income                                  |         | $                  | 10.8    |       |                    | $ | 36.1          |          |  | $ | 90.1        |      |  | $ | 115.4   |     
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     
|Net income per common share:                |         |                    |         |       |                    |   |               |          |  |   |             |      |  |   |         |     
|                                            | Basic   |                    | $       | 0.11  |                    |   | $             | 0.36     |  |   | $           | 1.19 |  |   | $       | 1.52 | 
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     
|                                            | Diluted |                    | $       | 0.10  |                    |   | $             | 0.34     |  |   | $           | 1.11 |  |   | $       | 1.42 | 
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     
|Weighted average common shares outstanding: |         |                    |         |       |                    |   |               |          |  |   |             |      |  |   |         |     
|                                            | Basic   |                    |         | 99.2  |                    |   |               | 99.2     |  |   |             | 75.7 |  |   |         | 75.7 | 
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     
|                                            | Diluted |                    |         | 106.0 |                    |   |               | 106.0    |  |   |             | 81.0 |  |   |         | 81.0 | 
|                                            |         |                    |         |       |                    |   |               |          |  |   |             |     

9



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)


BALANCE SHEET


(In millions, except share data)


|                                     |                                |                                            |         |         |             |   |         |         |         | 
|------------------------------------ | ------------------------------ | ------------------------------------------ | ------- | ------- | ----------- | - | ------- | ------- | ------- | 
|                                     |                                | September 30, 2004                         |        
|                                     |                                |                                            |        
|                                     |                                | As Previously                              |         |         |            
|                                     |                                | Reported                                   |         |         | As Restated |  
|                                     |                                |                                            |         |         |             |  
|ASSETS                               |                                |                                            |         |         |             |   |         |        
|Other current assets                 |                                | $                                          | 211.9   |         |             | $ | 215.1   |        
|                                     | Total current assets           |                                            |         | 1,806.1 |             |   |         | 1,809.3 |        
|Goodwill                             |                                |                                            | 4,193.2 |         |             |   | 4,193.4 |        
|Other assets                         |                                |                                            | 200.5   |         |             |   | 186.6   |        
|                                     | Total assets                   |                                            |         | 7,988.9 |             |   |         | 7,978.4 |        
|                                    
|LIABILITIES AND STOCKHOLDERS EQUITY |                                |                                            |         |         |             |   |         |        
|Other liabilities                    |                                | $                                          | 560.2   |         |             | $ | 752.5   |        
|                                     | Total liabilities              |                                            |         | 4,114.4 |             |   |         | 4,306.7 |        
|                                     | Capital in excess of par value |                                            |         | 4,183.4 |             |   |         | 3,955.3 |        
|                                     | Accumulated deficit            |                                            |         | (336.4  | )           |   |         | (311.1  | )      
|                                     |                                | Total stockholders equity                 |         |         | 3,874.5     |   |         |         | 3,671.7 | 
|                                     |                                | Total liabilities and stockholders equity |         |         | 7,988.9     |   |         |         | 7,978.4 | 

STATEMENT OF CASH FLOWS


(In millions)


|                                      |                                                                                   |                                              |        |      |             |   |        |       |      | 
|------------------------------------- | --------------------------------------------------------------------------------- | -------------------------------------------- | ------ | ---- | ----------- | - | ------ | ----- | ---- | 
|                                      |                                                                                   | Nine Months Ended                            |       
|                                      |                                                                                   | September 30, 2004                           |       
|                                      |                                                                                   |                                              |       
|                                      |                                                                                   | As Previously                                |        |      |            
|                                      |                                                                                   | Reported                                     |        |      | As Restated |  
|                                      |                                                                                   |                                              |        |      |             |  
|Cash flows from operating activities: |                                                                                   |                                              |        |      |             |   |        |      
|                                      | Net income                                                                        |                                              | $      | 90.1 |             |   | $      | 115.4 |     
|                                      | Adjustments to reconcile net income to cash provided by
    operating activities: |                                              |        |      |             |   |        |       |     
|                                      |                                                                                   | Depreciation and amortization                |        |      | 93.1        |   |        |       | 92.2 | 
|                                      |                                                                                   | Call premiums and deferred financing charges |        |      | 54.8        |   |        |       | 15.6 | 
|                                      |                                                                                   | Deferred income taxes                        |        |      | (2.0        | ) |        |       | 12.8 | 
|Cash flows from financing activities: |                                                                                   |                                              |        |      |             |   |        |      
|Payments of long-term debt            |                                                                                   |                                              | (704.0 | )    |             |   | (731.4 | )    
|Call premiums                         |                                                                                   |                                              | (29.7  | )    |             |   | (2.3   | )    



|         |                         
|-------- | ------------------------
|Note 2  | Stock-Based Compensation



10



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




|                                                                                                                 |         |               |      |      |               |   |      |      |  |   |       |      |  |   |       |      | 
|---------------------------------------------------------------------------------------------------------------- | ------- | ------------- | ---- | ---- | ------------- | - | ---- | ---- |  | - | ----- | ---- |  | - | ----- | ---- | 
|                                                                                                                 |         | Three Months  |      |      | Nine Months   |  
|                                                                                                                 |         | Ended         |      |      | Ended         |  
|                                                                                                                 |         | September 30, |      |      | September 30, |  
|                                                                                                                 |         |               |      |      |               |  
|                                                                                                                 |         | 2004          |      |      | 2003          |   |      | 2004 |  |   | 2003  |     
|                                                                                                                 |         |               |      |      |               |   |      |      |  |   |       |     
|Net income, as reported                                                                                          |         | $             | 36.1 |      |               | $ | 27.7 |      |  | $ | 115.4 |      |  | $ | 59.8  |     
|Deduct: stock-based compensation expense determined using fair
    value based method for all awards, net of tax |         |               | (7.4 | )    |               |   | (4.6 | )    |  |   | (21.9 | )    |  |   | (12.4 | )   
|                                                                                                                 |         |               |      |      |               |   |      |      |  |   |       |     
|Net income, pro forma                                                                                            |         | $             | 28.7 |      |               | $ | 23.1 |      |  | $ | 93.5  |      |  | $ | 47.4  |     
|                                                                                                                 |         |               |      |      |               |   |      |      |  |   |       |     
|Net income per common share                                                                                      |         |               |      |      |               |   |      |      |  |   |       |      |  |   |       |     
|As reported:                                                                                                     |         |               |      |      |               |   |      |      |  |   |       |      |  |   |       |     
|                                                                                                                 | Basic   |               | $    | 0.36 |               |   | $    | 0.50 |  |   | $     | 1.52 |  |   | $     | 1.09 | 
|                                                                                                                 |         |               |      |      |               |   |      |      |  |   |       |     
|                                                                                                                 | Diluted |               | $    | 0.34 |               |   | $    | 0.47 |  |   | $     | 1.42 |  |   | $     | 1.02 | 
|                                                                                                                 |         |               |      |      |               |   |      |      |  |   |       |     
|Pro forma:                                                                                                       |         |               |      |      |               |   |      |      |  |   |       |      |  |   |       |     
|                                                                                                                 | Basic   |               | $    | 0.29 |               |   | $    | 0.42 |  |   | $     | 1.24 |  |   | $     | 0.86 | 
|                                                                                                                 |         |               |      |      |               |   |      |      |  |   |       |     
|                                                                                                                 | Diluted |               | $    | 0.27 |               |   | $    | 0.39 |  |   | $     | 1.15 |  |   | $     | 0.81 | 
|                                                                                                                 |         |               |      |      |               |   |      |      |  |   |       |     



|                        |  |               |          |   |      |  |          |  
|----------------------- |  | ------------- | -------- | - | ---- |  | -------- | -
|                        |  | September 30, |         
|                        |  |               |         
|                        |  | 2004          |          |   | 2003 | 
|                        |  |               |          |   |      | 
|Risk free interest rate |  |               | 3.3      | % |      |  | 2.6      | %
|Expected life of option |  |               | 5  years |   |      |  | 5  years |  
|Volatility              |  |               | 39       | % |      |  | 41       | %
|Expected dividend yield |  |               | 0        | % |      |  | 0        | %



|         |                                      
|-------- | -------------------------------------
|Note 3  | Merger with Apogent Technologies Inc.







| |   |                                                                                                                                                                                                                                                                                                                            
| | - | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | Life-science market position. The Companys life-science
    footprint may grow substantially as a result of this
    combination. In addition, Apogents wide range of
    consumable products for protein-based research and other drug
    discovery applications will enhance the Companys
    life-science portfolio.
|
| |  | Biopharma-production and diagnostic-reagent offering. The
    combination of Fisher with Apogent may strengthen the
    Companys offerings in biopharma-production and
    diagnostic-reagents.                                                                                                                           

11



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




| |   |                                                                                                                                                                                                
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | Global market presence. Apogent has manufacturing operations
    throughout the world that may complement and enhance the
    Companys existing worldwide distribution and supply
    network.





| |   |                                                                                                                                                                                                                                                                                                                                   
| | - | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | Enhanced margins. The Company expects higher-margin, proprietary
    products to approximate 60 percent of its total annual
    sales. Accordingly, the Company projects that its operating
    margins will increase as a result of the combination.                                                                             
|
| |  | Synergy opportunities. The Company expects to achieve cost
    savings and other benefits in 2005 and beyond. These synergies
    may come from, among other things, facility consolidations,
    sourcing opportunities, administrative efficiencies and the
    elimination of duplicative marketing and distribution functions.
|
| |  | Earnings and revenue growth. The Company believes that its
    revenue and earnings may be enhanced as a result of the
    combination with Apogent.                                                                                                                                                                              
|
| |  | Operating cash flow. The Company anticipates cash flow from
    operations will increase as a result of the merger and could
    increase the financial flexibility that may enhance its ability
    to pursue strategic growth opportunities.                                                                                    



|                                                 |                         |   |         |         | 
|------------------------------------------------ | ----------------------- | - | ------- | ------- | 
|Aggregate value of stock consideration           |                         | $ | 2,658.8 |        
|Value of Apogent stock options assumed by Fisher |                         |   | 109.9   |        
|                                                 |                         |   |        
|                                                 | Aggregate consideration |   |         | 2,768.7 | 
|Tax benefit of Apogent stock options exercised   |                         |   | (17.1   | )      
|                                                 |                         |   |        
|                                                 | Net consideration       |   | $       | 2,751.6 | 
|                                                 |                         |   |        





12



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




|                               |                           |               |         |         | 
|------------------------------ | ------------------------- | ------------- | ------- | ------- | 
|                               |                           | (In millions) |        
|                               |                           |               |        
|Current Assets                 |                           | $             | 676.7   |        
|Property, plant, and equipment |                           |               | 268.1   |        
|Intangible assets              |                           |               | 694.0   |        
|Goodwill                       |                           |               | 2,866.6 |        
|Other assets                   |                           |               | 27.7    |        
|                               |                           |               |        
|                               | Total assets acquired     |               |         | 4,533.1 | 
|                               |                           |               |        
|Current liabilities            |                           |               | 278.7   |        
|Long-term debt                 |                           |               | 1,056.7 |        
|Other liabilities              |                           |               | 446.1   |        
|                               |                           |               |        
|                               | Total liabilities assumed |               |         | 1,781.5 | 
|                               |                           |               |        
|                               | Net assets acquired       |               | $       | 2,751.6 | 
|                               |                           |               |        





| |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | The Company assumed $250 million aggregate principal amount
    of the
    61/2% senior
    subordinated notes due 2013 (the
    61/2% Notes).
    The
    61/2% Notes
    were recorded at a fair value of $276.9 million based upon
    the tender price for the notes, which was $1,107.50 in cash per
    $1,000 principal amount, plus accrued and unpaid interest. The
    61/2% Notes
    were tendered and a consent was given to amend the indenture for
    any notes that remained outstanding to eliminate restrictive
    covenants in that indenture. The cash tender offer was completed
    concurrently with the merger.                
|
| |  | The Company assumed $300 million aggregate principal amount
    of 2.25% Senior Convertible Contingent Debt Securities due
    2021 (the 2.25% CODES). The 2.25% CODES were
    recorded at a fair value of $335.4 million based upon the
    market price for the debt security at July 30, 2004,
    reflecting a premium of $33.9 million and a liability of
    $1.5 million for exchange fees to be paid. The Company
    determined that the premium was due to the equity conversion
    feature of the debt and recorded the amount of the premium to
    capital in excess of par value.                                                        
|
| |  | The Company assumed $345 million aggregate principal amount
    of Floating Rate Senior Convertible Contingent Debt Securities
    due 2033 (the Floating Rate CODES). The Floating
    Rate CODES were recorded at a fair value of $426.3 million
    based upon the market price for such debt securities at
    July 30, 2004, reflecting a premium of $77.5 million
    and a liability of $3.8 million for exchange and consent
    solicitation fees to be paid. The Company determined that the
    premium was due to the equity conversion feature of the debt and
    recorded the amount of the premium to capital in excess of par
    value.
|
| |  | The Company assumed $7 million of remaining aggregate
    principal amount of 8% senior notes due 2011 (the
    8% Notes). The 8% Notes were recorded at a
    fair value of $7.6 million based upon the market value for
    the debt security at July 30, 2004, reflecting a premium of
    $0.6 million.                                                                                                                                                                                                                                                                                                                                              

13



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)






|                             |         |                    |         |      |                   |   |         |       |   |   |         |      |  |   |         |      | 
|---------------------------- | ------- | ------------------ | ------- | ---- | ----------------- | - | ------- | ----- | - | - | ------- | ---- |  | - | ------- | ---- | 
|                             |         | Three Months Ended |         |      | Nine Months Ended |  
|                             |         | September 30,      |         |      | September 30,     |  
|                             |         |                    |         |      |                   |  
|                             |         | 2004               |         |      | 2003              |   |         | 2004  |   |   | 2003    |     
|                             |         |                    |         |      |                   |   |         |       |   |   |         |     
|Sales                        |         | $                  | 1,355.8 |      |                   | $ | 1,135.3 |       |   | $ | 3,941.8 |      |  | $ | 3,309.5 |     
|Net income                   |         | $                  | 29.6    |      |                   | $ | (21.7   | )     |   | $ | 154.9   |      |  | $ | 54.6    |     
|Net income per common share: |         |                    |         |      |                   |   |         |       |   |   |         |      |  |   |         |     
|                             | Basic   |                    | $       | 0.26 |                   |   | $       | (0.21 | ) |   | $       | 1.35 |  |   | $       | 0.52 | 
|                             | Diluted |                    | $       | 0.24 |                   |   | $       | (0.21 | ) |   | $       | 1.25 |  |   | $       | 0.49 | 



|         |             
|-------- | ------------
|Note 4  | Acquisitions





|                              |                           |               |       |       | 
|----------------------------- | ------------------------- | ------------- | ----- | ----- | 
|                              |                           | (In millions) |      
|                              |                           |               |      
|Current Assets                |                           | $             | 145.5 |      
|Property, plant and equipment |                           |               | 62.5  |      
|Intangible assets             |                           |               | 112.0 |      
|Goodwill                      |                           |               | 518.1 |      
|                              |                           |               |      
|                              | Total assets acquired     |               |       | 838.1 | 
|                              |                           |               |      
|Current liabilities           |                           |               | 47.4  |      
|Other liabilities             |                           |               | 50.1  |      
|                              |                           |               |      
|                              | Total liabilities assumed |               |       | 97.5  | 
|                              |                           |               |      
|                              | Net assets acquired       |               | $     | 740.6 | 
|                              |                           |               |      



14



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)








|                             |         |                    |         |      |                   |   |       |      |  |   |         |      |  |   |         |      | 
|---------------------------- | ------- | ------------------ | ------- | ---- | ----------------- | - | ----- | ---- |  | - | ------- | ---- |  | - | ------- | ---- | 
|                             |         | Three Months Ended |         |      | Nine Months Ended |  
|                             |         | September 30,      |         |      | September 30,     |  
|                             |         |                    |         |      |                   |  
|                             |         | 2004               |         |      | 2003              |   |       | 2004 |  |   | 2003    |     
|                             |         |                    |         |      |                   |   |       |      |  |   |         |     
|Sales                        |         | $                  | 1,263.0 |      |                   | $ | 927.8 |      |  | $ | 3,361.2 |      |  | $ | 2,701.9 |     
|Net income                   |         | $                  | 36.1    |      |                   | $ | 29.6  |      |  | $ | 116.6   |      |  | $ | 65.7    |     
|Net income per common share: |         |                    |         |      |                   |   |       |      |  |   |         |      |  |   |         |     
|                             | Basic   |                    | $       | 0.36 |                   |   | $     | 0.54 |  |   | $       | 1.54 |  |   | $       | 1.20 | 
|                             | Diluted |                    | $       | 0.34 |                   |   | $     | 0.50 |  |   | $       | 1.44 |  |   | $       | 1.12 | 





|         |            
|-------- | -----------
|Note 5  | Inventories



|                  |       |               |       |       |              |   |       |       | 
|----------------- | ----- | ------------- | ----- | ----- | ------------ | - | ----- | ----- | 
|                  |       | September 30, |       |       | December 31, |  
|                  |       | 2004          |       |       | 2003         |  
|                  |       |               |       |       |              |  
|Raw materials     |       | $             | 136.1 |       |              | $ | 64.2  |      
|Work in process   |       |               | 61.3  |       |              |   | 22.6  |      
|Finished products |       |               | 454.0 |       |              |   | 268.6 |      
|                  |       |               |       |       |              |  
|                  | Total |               | $     | 651.4 |              |   | $     | 355.4 | 
|                  |       |               |       |       |              |  

15



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




|         |                                     
|-------- | ------------------------------------
|Note 6  | Goodwill and Other Intangible Assets



|                                 |                                   |              |         |         |              |   |         |              |  |   |       |   |  |   |         |         |  
|-------------------------------- | --------------------------------- | ------------ | ------- | ------- | ------------ | - | ------- | ------------ |  | - | ----- | - |  | - | ------- | ------- | -
|                                 |                                   | Scientific   |         |         | Healthcare   |   |         |              |  |  
|                                 |                                   | Products and |         |         | Products and |   |         | Laboratory   |  |   |      
|                                 |                                   | Services     |         |         | Services     |   |         | Workstations |  |   | Total |  
|                                 |                                   |              |         |         |              |   |         |              |  |   |       |  
|Balance as of December 31, 2003  |                                   | $            | 844.3   |         |              | $ | 109.6   |              |  | $ | 53.0  |   |  | $ | 1,006.9 |        
|Adjustments/allocations          |                                   |              | 4.6     |         |              |   | 45.7    |              |  |   |      |   |  |   | 50.3    |        
|                                 | Acquisitions(a)                   |              |         | 2,246.0 |              |   |         | 892.7        |  |   |       |  |  |   |         | 3,138.7 |  
|                                 | Effect of foreign currency change |              |         | (2.5    | )            |   |         |             |  |   |       |  |  |   |         | (2.5    | )
|                                 |                                   |              |         |         |              |   |         |              |  |   |       |  
|Balance as of September 30, 2004 |                                   | $            | 3,092.4 |         |              | $ | 1,048.0 |              |  | $ | 53.0  |   |  | $ | 4,193.4 |        
|                                 |                                   |              |         |         |              |   |         |              |  |   |       |  






|    |                                                                                                                                                                                                                                                                                                                                                                    
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(a) | The initial allocation of the purchase price for the Apogent,
    Dharmacon and Oxoid acquisitions, including certain adjustments
    recorded in connection with the restatements, are based on a
    preliminary valuation whereby data gathering is ongoing.
    Accordingly, these estimates will be revised when the evaluation
    is substantially complete.



|                                                                                                                                                                          |  |               |       |  |              |   |      | 
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  | ------------- | ----- |  | ------------ | - | ---- | 
|                                                                                                                                                                          |  | September 30, |       |  | December 31, |  
|                                                                                                                                                                          |  | 2004          |       |  | 2003         |  
|                                                                                                                                                                          |  |               |       |  |              |  
|Customer lists (net of accumulated amortization of
    $15.1 million and $10.2 million at September 30,
    2004 and December 31, 2003, respectively)                     |  | $             | 189.2 |  |              | $ | 38.1 | 
|Non-compete agreements (net of accumulated amortization of
    $20.8 million and $18.3 million at September 30,
    2004 and December 31, 2003 respectively)              |  |               | 5.4   |  |              |   | 3.2  | 
|Patents and tradenames (net of accumulated amortization of
    $9.3 million and $8.9 million at September 30,
    2004 and December 31, 2003, respectively)               |  |               | 9.0   |  |              |   | 8.5  | 
|Developed technology (net of accumulated amortization of
    $7.7 million and $2.9 million at September 30,
    2004 and December 31, 2003, respectively)                 |  |               | 196.6 |  |              |   | 16.6 | 
|Other amortizable intangible assets (net of accumulated
    amortization of $15.9 million and $8.0 million at
    September 30, 2004 and December 31, 2003, respectively) |  |               | 59.2  |  |              |   | 31.7 | 
|                                                                                                                                                                          |  |               |       |  |              |  
|                                                                                                                                                                          |  | $             | 459.4 |  |              | $ | 98.1 | 
|                                                                                                                                                                          |  |               |       |  |              |  



16



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




|                                |  |   |       | 
|------------------------------- |  | - | ----- | 
|For the Year Ended December 31, |  |  
|                                |  |  
|2004(b)                         |  | $ | 12.4  | 
|2005                            |  | $ | 46.9  | 
|2006                            |  | $ | 46.3  | 
|2007                            |  | $ | 43.2  | 
|2008                            |  | $ | 42.5  | 
|Thereafter                      |  | $ | 268.1 | 






|    |                                                                                                              
|--- | -------------------------------------------------------------------------------------------------------------
|(b) | Amount represents estimated amortization expense for the
    remaining three months ending December 31, 2004.





|         |                 
|-------- | ----------------
|Note 7  | Accounts Payable



17



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




|         |     
|-------- | ----
|Note 8  | Debt



|                                                                                                                                                                    |                      |               |       |         |              |   |       |         | 
|------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------- | ------------- | ----- | ------- | ------------ | - | ----- | ------- | 
|                                                                                                                                                                    |                      | September 30, |       |         | December 31, |  
|                                                                                                                                                                    |                      | 2004          |       |         | 2003         |  
|                                                                                                                                                                    |                      |               |       |         |              |  
|Term Facility                                                                                                                                                       |                      | $             | 396.5 |         |              | $ |      |        
|Prior credit facility                                                                                                                                               |                      |               |      |         |              |   | 440.0 |        
|Other Debt                                                                                                                                                          |                      |               | 49.1  |         |              |   | 36.2  |        
|71/8% notes
    due 2005                                                                                                                                            |                      |               | 0.1   |         |              |   | 0.4   |        
|2.50% Convertible Senior Notes due 2023 convertible at
    $47.46 per share                                                                                         |                      |               | 300.0 |         |              |   | 300.0 |        
|3.25% Convertible Senior Subordinated Notes due 2024
    convertible at $80.40 per share                                                                            |                      |               | 330.0 |         |              |   |      |        
|81/8% Senior
    Subordinated Notes due 2012 (includes $6.0 million and
    $6.4 million of premiums at September 30, 2004 and
    December 31, 2003, respectively) |                      |               | 310.0 |         |              |   | 310.4 |        
|8% Senior Subordinated Notes due 2013 (includes
    $10.5 million and $11.1 million of premiums at
    September 30, 2004 and December 31, 2003, respectively)      |                      |               | 310.5 |         |              |   | 311.1 |        
|2.25% Senior Convertible Contingent Debentures due 2021                                                                                                             |                      |               | 298.8 |         |              |   |      |        
|2.25% CODES due 2021                                                                                                                                                |                      |               | 1.0   |         |              |   |      |        
|Floating Rate Convertible Senior Debentures due 2033                                                                                                                |                      |               | 344.6 |         |              |   |      |        
|63/4% Senior
    Subordinated Notes due 2014                                                                                                                        |                      |               | 300.0 |         |              |   |      |        
|                                                                                                                                                                    |                      |               |       |         |              |  
|                                                                                                                                                                    | Total debt           |               |       | 2,640.6 |              |   |       | 1,398.1 | 
|Less: short-term portion                                                                                                                                            |                      |               | (38.1 | )       |              |   | (12.0 | )      
|                                                                                                                                                                    |                      |               |       |         |              |  
|                                                                                                                                                                    | Total long-term debt |               | $     | 2,602.5 |              |   | $     | 1,386.1 | 
|                                                                                                                                                                    |                      |               |       |         |              |  





18



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)






1 2 1 2 1 2 1 2 1 2 1 2




3 4 1 2






19



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)








|         |                   
|-------- | ------------------
|Note 9  | Other Expense, Net





|          |                       
|--------- | ----------------------
|Note 10  | Employee Benefit Plans



20



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




|                                                   |                                    |                                  |      |                |          |   |      |      |  |   |      |      |   |   |      |      |  
|-------------------------------------------------- | ---------------------------------- | -------------------------------- | ---- | -------------- | -------- | - | ---- | ---- |  | - | ---- | ---- | - | - | ---- | ---- | -
|                                                   |                                    | Three Months Ended September 30, |     
|                                                   |                                    |                                  |     
|                                                   |                                    |                                  |      | Other          |         
|                                                   |                                    |                                  |      | Postretirement |         
|                                                   |                                    | Pension Benefits                 |      |                | Benefits |  
|                                                   |                                    |                                  |      |                |          |  
|                                                   |                                    | 2004                             |      |                | 2003     |   |      | 2004 |  |   | 2003 |     
|                                                   |                                    |                                  |      |                |          |   |      |      |  |   |      |     
|Components of net periodic benefit (income) cost   |                                    |                                  |      |                |          |   |      |      |  |   |      |      |   |   |      |     
|Service cost                                       |                                    | $                                | 4.4  |                |          | $ | 3.2  |      |  | $ | 0.1  |      |   | $ | 0.1  |     
|Interest cost                                      |                                    |                                  | 6.3  |                |          |   | 4.7  |      |  |   | 0.5  |      |   |   | 0.4  |     
|Expect return on plan assets                       |                                    |                                  | (8.0 | )              |          |   | (6.2 | )    |  |   |     |      |   |   |     |     
|Amortization of unrecognized net (gain) loss       |                                    |                                  | 0.1  |                |          |   | 0.1  |      |  |   | (0.4 | )    |   |   | (0.6 | )   
|Amortization of unrecognized prior service benefit |                                    |                                  | 0.3  |                |          |   | (0.1 | )    |  |   | (0.6 | )    |   |   | (0.4 | )   
|Recognized net actuarial loss                      |                                    |                                  | 0.2  |                |          |   |     |      |  |   |     |      |   |   |     |     
|Settlement/curtailment loss                        |                                    |                                  | 0.3  |                |          |   | 0.3  |      |  |   |     |      |   |   |     |     
|                                                   |                                    |                                  |      |                |          |   |      |      |  |   |      |     
|                                                   | Net periodic benefit (income) cost |                                  | $    | 3.6            |          |   | $    | 2.0  |  |   | $    | (0.4 | ) |   | $    | (0.5 | )
|                                                   |                                    |                                  |      |                |          |   |      |      |  |   |      |     

|                                                   |                                    |                                 |       |                |          |   |       |      |  |   |      |      |   |   |      |      |  
|-------------------------------------------------- | ---------------------------------- | ------------------------------- | ----- | -------------- | -------- | - | ----- | ---- |  | - | ---- | ---- | - | - | ---- | ---- | -
|                                                   |                                    | Nine Months Ended September 30, |      
|                                                   |                                    |                                 |      
|                                                   |                                    |                                 |       | Other          |         
|                                                   |                                    |                                 |       | Postretirement |         
|                                                   |                                    | Pension Benefits                |       |                | Benefits |  
|                                                   |                                    |                                 |       |                |          |  
|                                                   |                                    | 2004                            |       |                | 2003     |   |       | 2004 |  |   | 2003 |     
|                                                   |                                    |                                 |       |                |          |   |       |      |  |   |      |     
|Components of net periodic benefit (income) cost   |                                    |                                 |       |                |          |   |       |      |  |   |      |      |   |   |      |     
|Service cost                                       |                                    | $                               | 11.7  |                |          | $ | 9.6   |      |  | $ | 0.3  |      |   | $ | 0.2  |     
|Interest cost                                      |                                    |                                 | 17.1  |                |          |   | 14.3  |      |  |   | 1.3  |      |   |   | 1.1  |     
|Expected return on plan assets                     |                                    |                                 | (22.3 | )              |          |   | (18.6 | )    |  |   |     |      |   |   |     |     
|Amortization of unrecognized net (gain) loss       |                                    |                                 | 0.3   |                |          |   | 0.3   |      |  |   | (1.3 | )    |   |   | (1.7 | )   
|Amortization of unrecognized prior service benefit |                                    |                                 | 0.9   |                |          |   | (0.3  | )    |  |   | (1.7 | )    |   |   | (1.2 | )   
|Recognized net actuarial loss                      |                                    |                                 | 0.6   |                |          |   |      |      |  |   |     |      |   |   |     |     
|Settlement/curtailment loss                        |                                    |                                 | 1.1   |                |          |   | 0.9   |      |  |   |     |      |   |   |     |     
|                                                   |                                    |                                 |       |                |          |   |       |      |  |   |      |     
|                                                   | Net periodic benefit (income) cost |                                 | $     | 9.4            |          |   | $     | 6.2  |  |   | $    | (1.4 | ) |   | $    | (1.6 | )
|                                                   |                                    |                                 |       |                |          |   |       |      |  |   |      |     



|          |                   
|--------- | ------------------
|Note 11  | Earnings Per Share



|                                                                                                     |  |               |       |  |               |  |      |      |  |  |      |  |  |  |      | 
|---------------------------------------------------------------------------------------------------- |  | ------------- | ----- |  | ------------- |  | ---- | ---- |  |  | ---- |  |  |  | ---- | 
|                                                                                                     |  | Three Months  |       |  | Nine Months   | 
|                                                                                                     |  | Ended         |       |  | Ended         | 
|                                                                                                     |  | September 30, |       |  | September 30, | 
|                                                                                                     |  |               |       |  |               | 
|                                                                                                     |  | 2004          |       |  | 2003          |  |      | 2004 |  |  | 2003 | 
|                                                                                                     |  |               |       |  |               |  |      |      |  |  |      | 
|Weighted average common shares outstanding used in computing
    basic net income per common share   |  |               | 99.2  |  |               |  | 55.2 |      |  |  | 75.7 |  |  |  | 54.9 | 
|Common stock equivalents(a)                                                                          |  |               | 6.8   |  |               |  | 4.2  |      |  |  | 5.3  |  |  |  | 3.6  | 
|                                                                                                     |  |               |       |  |               |  |      |      |  |  |      | 
|Weighted average common shares outstanding used in computing
    diluted net income per common share |  |               | 106.0 |  |               |  | 59.4 |      |  |  | 81.0 |  |  |  | 58.5 | 
|                                                                                                     |  |               |       |  |               |  |      |      |  |  |      | 

21



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)







|    |                                                                                                                                                                                                                                                                                                                                                                                                              
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(a) | The weighted average amount of outstanding antidilutive common
    stock options and warrants excluded from the computation of
    diluted net income (loss) per common share for the three and
    nine months ended September 30, 2004 was 0.4 million
    and 0.8 million respectively, and for the three and nine
    months ended September 30, 2003 was 2.4 million, and
    2.8 million, respectively.









|          |                    
|--------- | -------------------
|Note 12  | Segment Information



|       |                                  |                    |   |       |                   |  |   |       |       |  |      |         |         |  |   |         |         | 
|------ | -------------------------------- | ------------------ | - | ----- | ----------------- |  | - | ----- | ----- |  | ---- | ------- | ------- |  | - | ------- | ------- | 
|       |                                  | Three Months Ended |   |       | Nine Months Ended | 
|       |                                  | September 30,      |   |       | September 30,     | 
|       |                                  |                    |   |       |                   | 
|       |                                  | 2004               |   |       | 2003              |  |   | 2004  |       |  | 2003 |        
|       |                                  |                    |   |       |                   |  |   |       |       |  |      |        
|Sales: |                                  |                    |   |       |                   |  |   |       |       |  |      |         |         |  |   |        
|       | Scientific products and services |                    | $ | 945.9 |                   |  | $ | 632.8 |       |  | $    | 2,478.5 |         |  | $ | 1,804.4 |        
|       | Healthcare products and services |                    |   | 283.7 |                   |  |   | 212.6 |       |  |      | 747.5   |         |  |   | 642.2   |        
|       | Laboratory workstations          |                    |   | 44.5  |                   |  |   | 50.4  |       |  |      | 126.3   |         |  |   | 156.1   |        
|       | Eliminations                     |                    |   | (11.1 | )                 |  |   | (5.8  | )     |  |      | (20.7   | )       |  |   | (14.8   | )      
|       |                                  |                    |   |       |                   |  |   |       |       |  |      |        
|       |                                  | Total              |   | $     | 1,263.0           |  |   | $     | 890.0 |  |      | $       | 3,331.6 |  |   | $       | 2,587.9 | 
|       |                                  |                    |   |       |                   |  |   |       |       |  |      |        

22



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)


|                        |                                         |                   |   |       |               |  |   |      |      |  |      |       |       |  |   |       |       | 
|----------------------- | --------------------------------------- | ----------------- | - | ----- | ------------- |  | - | ---- | ---- |  | ---- | ----- | ----- |  | - | ----- | ----- | 
|                        |                                         | Three Months      |   |       | Nine Months   | 
|                        |                                         | Ended             |   |       | Ended         | 
|                        |                                         | September 30,     |   |       | September 30, | 
|                        |                                         |                   |   |       |               | 
|                        |                                         | 2004              |   |       | 2003          |  |   | 2004 |      |  | 2003 |      
|                        |                                         |                   |   |       |               |  |   |      |      |  |      |      
|Income from operations: |                                         |                   |   |       |               |  |   |      |      |  |      |       |       |  |   |      
|                        | Scientific products and services        |                   | $ | 112.3 |               |  | $ | 62.5 |      |  | $    | 255.1 |       |  | $ | 165.3 |      
|                        | Healthcare products and services        |                   |   | 33.6  |               |  |   | 7.3  |      |  |      | 61.0  |       |  |   | 26.1  |      
|                        | Laboratory workstations                 |                   |   | 0.8   |               |  |   | 2.9  |      |  |      | 1.9   |       |  |   | 9.3   |      
|                        | Eliminations                            |                   |   | (0.3  | )             |  |   | (0.1 | )    |  |      | (0.3  | )     |  |   | (0.3  | )    
|                        |                                         |                   |   |       |               |  |   |      |      |  |      |      
|                        |                                         | Segment sub-total |   |       | 146.4         |  |   |      | 72.6 |  |      |       | 317.7 |  |   |       | 200.4 | 
|                        | Inventory step-up                       |                   |   | (44.4 | )             |  |   | (4.5 | )    |  |      | (60.3 | )     |  |   | (4.5  | )    
|                        | Non-recurring integration-related costs |                   |   | (8.2  | )             |  |   |     |      |  |      | (9.7  | )     |  |   |      |      
|                        | Restructuring charges                   |                   |   | (1.6  | )             |  |   |     |      |  |      | (1.6  | )     |  |   |      |      
|                        |                                         |                   |   |       |               |  |   |      |      |  |      |      
|                        |                                         | Total             |   | $     | 92.2          |  |   | $    | 68.1 |  |      | $     | 246.1 |  |   | $     | 195.9 | 
|                        |                                         |                   |   |       |               |  |   |      |      |  |      |      





|          |                                 
|--------- | --------------------------------
|Note 13  | Recent Accounting Pronouncements





23



---



##### Table of Contents



FISHER SCIENTIFIC INTERNATIONAL INC.


NOTES TO FINANCIAL STATEMENTS  (Continued)




|                                       |                                                    |               |      |       |               |   |      |      |  |   |       |      |  |   |      |      | 
|-------------------------------------- | -------------------------------------------------- | ------------- | ---- | ----- | ------------- | - | ---- | ---- |  | - | ----- | ---- |  | - | ---- | ---- | 
|                                       |                                                    | Three Months  |      |       | Nine Months   |  
|                                       |                                                    | Ended         |      |       | Ended         |  
|                                       |                                                    | September 30, |      |       | September 30, |  
|                                       |                                                    |               |      |       |               |  
|                                       |                                                    | 2004          |      |       | 2003          |   |      | 2004 |  |   | 2003  |     
|                                       |                                                    |               |      |       |               |   |      |      |  |   |       |     
|Net income, as reported                |                                                    | $             | 36.1 |       |               | $ | 27.7 |      |  | $ | 115.4 |      |  | $ | 59.8 |     
|                                       |                                                    |               |      |       |               |   |      |      |  |   |       |     
|Net income per share                   |                                                    |               |      |       |               |   |      |      |  |   |       |      |  |   |      |     
|As reported:                           |                                                    |               |      |       |               |   |      |      |  |   |       |      |  |   |      |     
|                                       | Diluted EPS                                        |               | $    | 0.34  |               |   | $    | 0.47 |  |   | $     | 1.42 |  |   | $    | 1.02 | 
|                                       |                                                    |               |      |       |               |   |      |      |  |   |       |     
|                                       | Diluted weighted average common shares outstanding |               |      | 106.0 |               |   |      | 59.4 |  |   |       | 81.0 |  |   |      | 58.5 | 
|                                       |                                                    |               |      |       |               |   |      |      |  |   |       |     
|Restated in accordance with EITF 04-08 |                                                    |               |      |       |               |   |      |      |  |   |       |      |  |   |      |     
|Diluted EPS                            |                                                    | $             | 0.34 |       |               | $ | 0.47 |      |  | $ | 1.42  |      |  | $ | 1.02 |     
|                                       |                                                    |               |      |       |               |   |      |      |  |   |       |     
|                                       | Diluted weighted average common shares outstanding |               |      | 106.3 |               |   |      | 59.4 |  |   |       | 81.0 |  |   |      | 58.5 | 
|                                       |                                                    |               |      |       |               |   |      |      |  |   |       |     





|          |                  
|--------- | -----------------
|Note 14  | Subsequent Events



24



---



##### Table of Contents








|         |                                                                                          
|-------- | -----------------------------------------------------------------------------------------
|Item 2  | Managements Discussion and Analysis of Financial
    Condition and Results of Operations



Overview
















25



---



##### Table of Contents















26



---



##### Table of Contents



Results of Operations




| |      
| | -----
| | Sales



|                                 |       |                                  |       |         |        |  |       |       |       |  |        |       |  |  |      |     |  
|-------------------------------- | ----- | -------------------------------- | ----- | ------- | ------ |  | ----- | ----- | ----- |  | ------ | ----- |  |  | ---- | --- | -
|                                 |       | Three Months Ended September 30, |      
|                                 |       |                                  |      
|                                 |       | 2004                             |       |         | 2003   | 
|                                 |       |                                  |       |         |        | 
|                                 |       |                                  |       | Sales   |        |  |       |       | Sales | 
|                                 |       | Sales                            |       |         | Growth |  |       | Sales |       |  | Growth |      
|                                 |       |                                  |       |         |        |  |       |       |       |  |        |      
|Scientific products and services |       | $                                | 945.9 |         |        |  | 49.5  | %     |       |  | 632.8  |       |  |  | 7.7  | %  
|Healthcare products and services |       |                                  | 283.7 |         |        |  | 33.4  | %     |       |  | 212.6  |       |  |  | 5.0  | %  
|Laboratory workstations          |       |                                  | 44.5  |         |        |  | (11.7 | )%    |       |  | 50.4   |       |  |  | 10.3 | %  
|Eliminations                     |       |                                  | (11.1 | )       |        |  |       |       |       |  | (5.8   | )     |  |  |      |    
|                                 |       |                                  |       |         |        |  |       |       |       |  |        |      
|                                 | Total |                                  | $     | 1,263.0 |        |  |       | 41.9  | %     |  | $      | 890.0 |  |  |      | 7.1 | %
|                                 |       |                                  |       |         |        |  |       |       |       |  |        |      

|                                 |       |                                 |         |         |        |  |       |       |       |   |         |         |  |  |     |     |  
|-------------------------------- | ----- | ------------------------------- | ------- | ------- | ------ |  | ----- | ----- | ----- | - | ------- | ------- |  |  | --- | --- | -
|                                 |       | Nine Months Ended September 30, |        
|                                 |       |                                 |        
|                                 |       | 2004                            |         |         | 2003   | 
|                                 |       |                                 |         |         |        | 
|                                 |       |                                 |         | Sales   |        |  |       |       | Sales |  
|                                 |       | Sales                           |         |         | Growth |  |       | Sales |       |   | Growth  |        
|                                 |       |                                 |         |         |        |  |       |       |       |   |         |        
|Scientific products and services |       | $                               | 2,478.5 |         |        |  | 37.4  | %     |       | $ | 1,804.4 |         |  |  | 6.3 | %  
|Healthcare products and services |       |                                 | 747.5   |         |        |  | 16.4  | %     |       |   | 642.2   |         |  |  | 7.2 | %  
|Laboratory workstations          |       |                                 | 126.3   |         |        |  | (19.1 | )%    |       |   | 156.1   |         |  |  | 1.5 | %  
|Eliminations                     |       |                                 | (20.7   | )       |        |  |       |       |       |   | (14.8   | )       |  |  |     |    
|                                 |       |                                 |         |         |        |  |       |       |       |   |         |        
|                                 | Total |                                 | $       | 3,331.6 |        |  |       | 28.7  | %     |   | $       | 2,587.9 |  |  |     | 7.1 | %
|                                 |       |                                 |         |         |        |  |       |       |       |   |         |        



Scientific Products and Services.


27



---



##### Table of Contents



Healthcare Products and Services.


Laboratory Workstations.




| |                       
| | ----------------------
| | Income from Operations



|                                        |                  |                                  |       |               |              |   |      |      |  |  |      |      |   |  |     |     |  
|--------------------------------------- | ---------------- | -------------------------------- | ----- | ------------- | ------------ | - | ---- | ---- |  |  | ---- | ---- | - |  | --- | --- | -
|                                        |                  | Three Months Ended September 30, |      
|                                        |                  |                                  |      
|                                        |                  |                                  |       | Income from   |             
|                                        |                  |                                  |       | Operations as |             
|                                        |                  | Income from                      |       |               | a Percentage |  
|                                        |                  | Operations                       |       |               | of Sales     |  
|                                        |                  |                                  |       |               |              |  
|                                        |                  | 2004                             |       |               | 2003         |   |      | 2004 |  |  | 2003 |     
|                                        |                  |                                  |       |               |              |   |      |      |  |  |      |     
|Scientific products and services        |                  | $                                | 112.3 |               |              | $ | 62.5 |      |  |  | 11.9 | %    |   |  | 9.9 | %  
|Healthcare products and services        |                  |                                  | 33.6  |               |              |   | 7.3  |      |  |  | 11.8 | %    |   |  | 3.4 | %  
|Laboratory workstations                 |                  |                                  | 0.8   |               |              |   | 2.9  |      |  |  | 1.8  | %    |   |  | 5.8 | %  
|Eliminations                            |                  |                                  | (0.3  | )             |              |   | (0.1 | )    |  |  |      |      |   |  |     |    
|                                        |                  |                                  |       |               |              |   |      |      |  |  |      |     
|                                        | Segment subtotal |                                  |       | 146.4         |              |   |      | 72.6 |  |  |      | 11.6 | % |  |     | 8.2 | %
|Inventory step-up                       |                  |                                  | (44.4 | )             |              |   | (4.5 | )    |  |  |      |      |   |  |     |    
|Non-recurring integration-related costs |                  |                                  | (8.2  | )             |              |   |     |      |  |  |      |      |   |  |     |    
|Restructuring charges                   |                  |                                  | (1.6  | )             |              |   |     |      |  |  |      |      |   |  |     |    
|                                        |                  |                                  |       |               |              |   |      |      |  |  |      |     
|                                        | Total            |                                  | $     | 92.2          |              |   | $    | 68.1 |  |  |      | 7.3  | % |  |     | 7.7 | %
|                                        |                  |                                  |       |               |              |   |      |      |  |  |      |     

|                                        |                  |                                 |       |               |              |   |       |       |  |  |      |     |   |  |     |     |  
|--------------------------------------- | ---------------- | ------------------------------- | ----- | ------------- | ------------ | - | ----- | ----- |  |  | ---- | --- | - |  | --- | --- | -
|                                        |                  | Nine Months Ended September 30, |      
|                                        |                  |                                 |      
|                                        |                  |                                 |       | Income from   |             
|                                        |                  |                                 |       | Operations as |             
|                                        |                  | Income from                     |       |               | a Percentage |  
|                                        |                  | Operations                      |       |               | of Sales     |  
|                                        |                  |                                 |       |               |              |  
|                                        |                  | 2004                            |       |               | 2003         |   |       | 2004  |  |  | 2003 |    
|                                        |                  |                                 |       |               |              |   |       |       |  |  |      |    
|Scientific products and services        |                  | $                               | 255.1 |               |              | $ | 165.3 |       |  |  | 10.3 | %   |   |  | 9.2 | %  
|Healthcare products and services        |                  |                                 | 61.0  |               |              |   | 26.1  |       |  |  | 8.2  | %   |   |  | 4.1 | %  
|Laboratory workstations                 |                  |                                 | 1.9   |               |              |   | 9.3   |       |  |  | 1.5  | %   |   |  | 6.0 | %  
|Eliminations                            |                  |                                 | (0.3  | )             |              |   | (0.3  | )     |  |  |      |     |   |  |     |    
|                                        |                  |                                 |       |               |              |   |       |       |  |  |      |    
|                                        | Segment subtotal |                                 |       | 317.7         |              |   |       | 200.4 |  |  |      | 9.5 | % |  |     | 7.7 | %
|Inventory step-up                       |                  |                                 | (60.3 | )             |              |   | (4.5  | )     |  |  |      |     |   |  |     |    
|Non-recurring integration-related costs |                  |                                 | (9.7  | )             |              |   |      |       |  |  |      |     |   |  |     |    
|Restructuring charges                   |                  |                                 | (1.6  | )             |              |   |      |       |  |  |      |     |   |  |     |    
|                                        |                  |                                 |       |               |              |   |       |       |  |  |      |    
|                                        | Total            |                                 | $     | 246.1         |              |   | $     | 195.9 |  |  |      | 7.4 | % |  |     | 7.6 | %
|                                        |                  |                                 |       |               |              |   |       |       |  |  |      |    



28



---



##### Table of Contents





Scientific Products and Services.


Healthcare Products and Services.


Laboratory Workstations.


Interest Expense




Other Expense, Net




Income Tax Provision




29



---



##### Table of Contents





| |                                
| | -------------------------------
| | Liquidity and Capital Resources











| |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
| | - | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | On February 12, 2004, we amended our existing
    $225 million receivables securitization facility extending
    the facilitys maturity date to February 2005. All other
    material terms and conditions under the receivables
    securitization facility remained unchanged.                                                                                                                                                                                                                                                                                                                                                        
|
| |  | On March 3, 2004, we sold $300 million of our
    3.25% convertible senior subordinated notes due 2024 and on
    March 23, 2004 sold an additional $30 million
    principal amount upon exercise of the over allotment option by
    the initial purchasers of the notes. These notes were issued
    pursuant to our registration statement on Form S-3 filed
    with the SEC on September 15, 2003, under which we can
    issue up to $750 million of debt and equity securities. In
    connection with the sale of the 3.25% convertible senior
    subordinated notes, we paid approximately $7.8 million in
    financing fees.
|
| |  | On March 31, 2004, we retired $80 million of bank debt
    outstanding under our term loan facility reducing the
    outstanding balance to $360 million.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
|
| |  | On August 3, 2004 we issued and sold pursuant to
    Rule 144A of $300 million of our
    63/4% senior
    subordinated notes due 2014. We used the proceeds from this
    offering to repay Apogents
    61/2% Senior
    Subordinated Notes due 2013.                                                                                                                                                                                                                                                                                                                                                                                 





| |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
| | - | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |  | We entered into a new credit facility (the New Credit
    Facility) to replace our existing credit facility, to pay
    off other existing indebtedness (including indebtedness of our
    subsidiaries), to provide working capital and for general
    corporate purposes. The New Credit Facility consists of
    (i) a $500 million revolving credit facility (the
    New Revolving Credit Facility) and (ii) a
    $700 million term loan facility (the New Term
    Loan Facility) in three tranches: (A) a
    $250 million tranche (Tranche A-1), (B) a
    $300 million tranche (Tranche A-2),
    currently not funded, and (C) a $150 million tranche
    (Tranche B). In addition, we have the ability,
    upon satisfaction of certain conditions, to request incremental
    term loans from the lenders under the New Credit Facility.
|
| |  | Fishers wholly-owned subsidiary, Apogent, completed an
    exchange offer for its $345 million aggregate principal
    amount of Floating Rate Senior Convertible Contingent Debt
    Securities due 2033 (the Floating Rate CODES). The
    exchange offer for the Floating Rate CODES aligned the
    conversion terms of Apogents convertible debt with
    Fishers currently outstanding convertible debt.
    99.9 percent of the outstanding principal amount of the
    Floating Rate CODES were tendered for exchange with a like
    principal amount of Floating Rate Convertible Senior Debentures
    and an exchange fee of                                                                                                                                                                                                                     

30



---



##### Table of Contents



| |   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
| | - | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| |   | 0.50 percent of the principal amount of the securities
    tendered was paid. In addition, Apogent paid a consent fee of
    0.60 percent to not register the notes as required per the
    original registration rights agreement. Neither Fisher nor
    Apogent will receive any proceeds from the issuance of the new
    debt securities in the exchange offer. Neither Fisher nor
    Apogent will receive any proceeds from the issuance of the new
    debentures in the exchange offer.                                                                                                                                                                                                                                                                               
|
| |  | Fishers wholly-owned subsidiary, Apogent completed an
    exchange offer for its $300 million aggregate principal
    amount of 2.25% Senior Convertible Contingent Debt
    Securities due 2021 (the 2.25% CODES). The exchange
    offer for the 2.25% CODES aligned the conversion terms of
    Apogents convertible debt with Fishers currently
    outstanding convertible debt. 99.6 percent of the
    outstanding principal amount of the 2.25% CODES were tendered
    for exchange with a like principal amount of 2.25% Senior
    Convertible Contingent Debt Securities and an exchange fee of
    0.50 percent of the principal amount of the securities
    tendered was paid.                                                                             
|
| |  | Concurrently with the two exchange offers, Fishers
    wholly-owned subsidiary, Apogent completed a cash tender offer
    for the $250 million aggregate principal amount of the
    61/2% Senior
    Subordinated Notes due 2013. Apogent accepted for payment
    $249.6 million aggregate principal amount representing
    99.8 percent of the outstanding principal amount of the
    61/2% Senior
    Subordinated Notes due 2013. The purchase price for the notes
    was $1,107.50 in cash per $1,000 principal amount, plus accrued
    and unpaid interest. A concurrent consent solicitation amended
    the indenture for any
    61/2% senior
    subordinated notes that remained outstanding to eliminate
    certain restrictive covenants in that indenture.







|                                                              |                               |                        |         |           |        |   |      |           |           |   |           |       |  |         |       |       |  |   |         |         | 
|------------------------------------------------------------- | ----------------------------- | ---------------------- | ------- | --------- | ------ | - | ---- | --------- | --------- | - | --------- | ----- |  | ------- | ----- | ----- |  | - | ------- | ------- | 
|                                                              |                               | Payments Due by Period |        
|                                                              |                               |                        |        
|                                                              |                               |                        |         | Less than |        |   |      |           | More than |  
|                                                              |                               | Total                  |         |           | 1 Year |   |      | 1-3 Years |           |   | 3-5 Years |       |  | 5 Years |      
|                                                              |                               |                        |         |           |        |   |      |           |           |   |           |       |  |         |      
|Debt, including short-term debt(a)                            |                               | $                      | 2,639.4 |           |        | $ | 37.6 |           |           | $ | 54.0      |       |  | $       | 194.9 |       |  | $ | 2,352.9 |        
|Capital lease obligations                                     |                               |                        | 1.2     |           |        |   | 0.6  |           |           |   | 0.6       |       |  |         |      |       |  |   |        |        
|Operating leases                                              |                               |                        | 172.0   |           |        |   | 45.3 |           |           |   | 50.5      |       |  |         | 36.3  |       |  |   | 39.9    |        
|Unconditional purchase obligations(b)                         |                               |                        | 1.8     |           |        |   | 1.4  |           |           |   | 0.4       |       |  |         |      |       |  |   |        |        
|Other long-term liabilities reflected on the balance sheet(s) |                               |                        | 14.0    |           |        |   |     |           |           |   | 6.8       |       |  |         | 3.1   |       |  |   | 4.1     |        
|                                                              |                               |                        |         |           |        |   |      |           |           |   |           |       |  |         |      
|                                                              | Total Contractual Obligations |                        | $       | 2,828.4   |        |   | $    | 84.9      |           |   | $         | 112.3 |  |         | $     | 234.3 |  |   | $       | 2,396.9 | 
|                                                              |                               |                        |         |           |        |   |      |           |           |   |           |       |  |         |      






|    |  |                                                                                                                                                                                                                                                                                                                                                                                                                                          
|--- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|(a) |  | Amounts represent the expected cash payments for our debt and do
    not include any unamortized discounts or premiums and deferred
    issuance costs.                                                                                                                                                                                                                                                                                  
|   
|(b) |  | Unconditional purchase obligations include agreements to
    purchase goods or services that are enforceable and legally
    binding and that specify all significant terms, including: fixed
    or minimum quantities to be purchased; fixed, minimum or
    variable price provisions; and the approximate timing of the
    transaction. Purchase obligations exclude agreements that are
    cancelable at any time without penalty.
|   
|(c) |  | Includes only long-term liabilities where both the timing and
    amount of payment streams are known.                                                                                                                                                                                                                                                                                                                                   



31



---



##### Table of Contents





Critical Accounting Policies




Convertible Notes






32



---



##### Table of Contents









Stock Options


Recent Accounting Pronouncements









|         |                                                               
|-------- | --------------------------------------------------------------
|Item 3  | Quantitative and Qualitative Disclosures About Market
    Risk







33



---



##### Table of Contents
















|         |                        
|-------- | -----------------------
|Item 4  | Controls and Procedures







34



---



##### Table of Contents















35



---



##### Table of Contents






PART II  OTHER INFORMATION







| |          |                                                    
| | -------- | ---------------------------------------------------
| | Item 4  | Submission of Matters to a Vote of Security Holders








| |          |                                
| | -------- | -------------------------------
| | Item 6  | Exhibit and Reports on Form 8-K





| |                |                                                                                                                                          
| | -------------- | -----------------------------------------------------------------------------------------------------------------------------------------
| | Exhibit 10.1*: | Form of Non-qualified Stock Option Agreement pursuant to the
    Fisher Scientific International Inc. 2001 Equity and Incentive
    Plan.
|
| | Exhibit 10.2*: | Form of Non-qualified Stock Option Agreement pursuant to the
    Fisher Scientific International Inc. 2003 Equity and Incentive
    Plan.



| |               |                                                                                                                                
| | ------------- | -------------------------------------------------------------------------------------------------------------------------------
| | Exhibit 31.1: | Certification pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.                                                   
|
| | Exhibit 31.2: | Certification pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.                                                   
|
| | Exhibit 32.1: | Certification pursuant to 18 U.S.C. Section 1350, as
    adopted pursuant to Section 906 of the Sarbanes-Oxley Act
    of 2002.
|
| | Exhibit 32.2: | Certification pursuant to 18 U.S.C. Section 1350, as
    adopted pursuant to Section 906 of the Sarbanes-Oxley Act
    of 2002.






|  |                                                       
|- | ------------------------------------------------------
|* | Filed with the original Quarterly Report on Form 10-Q.

36



---



##### Table of Contents






SIGNATURE






| |                                             
| | --------------------------------------------
| | Fisher Scientific
    International Inc.    
|
| | /s/ Kevin P. Clark                          
| |                                             
| | Kevin P. Clark                              
| | Vice President and Chief Financial Officer  
| | (Principal Financial and Accounting Officer)



37